Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.68 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.60 |
| ▸ | BRAF | P15056 | 4/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.60 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.60 |
| ▸ | RAF1 | P04049 | 7/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260334 | 0.90 | KDR (0.78) | KDRNTRK1BRAFMAPK14TNNI3K | |
| SCHEMBL2333774 | 0.87 | KDR (0.61) | KDRNTRK1BRAFMAPK14TNNI3K | |
| SCHEMBL2333147 | 0.86 | KDR (0.73) | KDRNTRK1BRAFMAPK14TNNI3K | |
| SCHEMBL2329806 | 0.86 | KDR (0.62) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL2333345 | 0.85 | KDR (0.59) | KDRNTRK1BRAFMAPK14TNNI3K | |
| SCHEMBL2334638 | 0.85 | ALDH1A1 (0.63) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL9945346 | 0.84 | KDR (0.73) | KDRNTRK1BRAFMAPK14TNNI3K | |
| SCHEMBL4253679 | 0.82 | KDR (1.00) | KDRNTRK1BRAFMAPK14TNNI3K | |
| SCHEMBL937617 | 0.81 | KDR (0.69) | KDRBRAFMAPK14TNNI3KRAF1 | |
| SCHEMBL2339137 | 0.80 | KDR (0.65) | KDRRAF1TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | claimed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | claimed |
| EP-1799669-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006040056-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | claimed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| WO-2012082746-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | MERCK PATENT GMBH | 2009-08-27 | — | — | US | disclosed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1799669-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006040056-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | KDR 993/4885NTRK1 828/4885BRAF 39/4885 |
| US-20090215799-A1 | HETEROCYCLIC SUBSTITUTED BISARYLUREA DERIVATIVES | ABL1, BTK, PRKACA | KDR 967/4885NTRK1 3060/4885BRAF 6/4885 |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KDR 4644/4885NTRK1 3659/4885BRAF 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.